| Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL (NCT01754857) | University of Wisconsin, Madison | 2013-11-12 |
| A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) (NCT02004522) | SecuraBio | 2013-11-01 |
| A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma (NCT01973387) | Janssen Research & Development, LLC | 2013-10-28 |
| Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (NCT01862445) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2013-10-01 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) (NCT01804686) | Janssen Research & Development, LLC | 2013-09-09 |
| BR in Patients With CLL With Comorbidities and/or Renal Dysfunction (NCT01832922) | Dartmouth-Hitchcock Medical Center | 2013-04-01 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (NCT01787409) | Mayo Clinic | 2013-03-06 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (NCT01728207) | Gilead Sciences | 2013-03-01 |
| Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL (NCT01400685) | Massachusetts General Hospital | 2012-12-01 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies (NCT01744912) | TG Therapeutics, Inc. | 2012-11-21 |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) (NCT01650727) | Merck Sharp & Dohme LLC | 2012-10-01 |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01611090) | Janssen Research & Development, LLC | 2012-09-19 |
| Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT01699152) | Tragara Pharmaceuticals, Inc. | 2012-09-01 |
| A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT01682616) | AbbVie | 2012-07-25 |
| A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT01578707) | Pharmacyclics LLC. | 2012-06-01 |
| Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL (NCT01496976) | H. Lee Moffitt Cancer Center and Research Institute | 2012-03-30 |
| Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT01497496) | H. Lee Moffitt Cancer Center and Research Institute | 2012-01-26 |
| Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01351896) | National Cancer Institute (NCI) | 2011-11-02 |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) (NCT01419691) | University of Kansas Medical Center | 2011-09-01 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas (NCT01314014) | University of Rochester | 2011-05-01 |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (NCT01282424) | Gilead Sciences | 2011-03-18 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma (NCT01306643) | Gilead Sciences | 2011-02-01 |
| Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) (NCT01292135) | Pharmacyclics LLC. | 2011-02-01 |
| Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma (NCT01239394) | Massachusetts General Hospital | 2010-12-01 |
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL (NCT01217749) | Pharmacyclics LLC. | 2010-12-01 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma (NCT01239875) | Mayo Clinic | 2010-11-01 |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia (NCT01161511) | Xencor, Inc. | 2010-09-01 |
| Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL (NCT01241786) | Hackensack Meridian Health | 2010-07-01 |
| Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL (NCT01173679) | Massachusetts General Hospital | 2010-07-01 |
| Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL (NCT01145209) | National Heart, Lung, and Blood Institute (NHLBI) | 2010-07-01 |
| A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers (NCT01117142) | National Heart, Lung, and Blood Institute (NHLBI) | 2010-06-03 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01109069) | Pharmacyclics LLC. | 2010-06-01 |
| Safety of PCI-32765 in Chronic Lymphocytic Leukemia (NCT01105247) | Pharmacyclics LLC. | 2010-05-01 |
| Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) (NCT01010568) | Georgetown University | 2010-04-01 |
| Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01002755) | M.D. Anderson Cancer Center | 2010-01-19 |
| Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL (NCT00974233) | University of Wisconsin, Madison | 2009-10-01 |
| Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT00873457) | Daphne Friedman | 2009-08-01 |
| Study of Repeat Intranodal Injections of Ad-ISF35 (NCT00942409) | Januario Castro, M.D. | 2009-06-01 |
| Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT00849524) | Januario Castro, M.D. | 2009-01-01 |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia (NCT00759603) | M.D. Anderson Cancer Center | 2008-09-01 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) (NCT00923507) | National Heart, Lung, and Blood Institute (NHLBI) | 2008-05-29 |
| Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older (NCT00535873) | M.D. Anderson Cancer Center | 2007-10-01 |
| Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT00439231) | Georg Aue, M.D. | 2007-02-01 |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (NCT00801281) | Polish Lymphoma Research Group | 2007-02-01 |
| Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT00850057) | University of California, San Diego | 2006-02-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00290004) | Pharmacyclics LLC. | 2005-11-01 |
| Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies (NCT00275431) | Ascenta Therapeutics | 2005-11-01 |
| Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma (NCT01000753) | Children's Oncology Group | 2005-05-30 |
| Unrelated Donor Stem Cell Transplantation (NCT01364363) | Scripps Health | 2005-03-01 |
| Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00100711) | Pharmacyclics LLC. | 2004-10-01 |
| Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT00193518) | SCRI Development Innovations, LLC | 2004-04-01 |
| Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT00201682) | John Byrd | 2002-10-01 |
| Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia (NCT00022971) | National Cancer Institute (NCI) | 2001-08-15 |